Treating cervical cancer cells with AHCC

Cancer cells 1
Treating cervical cancer cells with AHCC 3

In study presented at the Society of Gynecological Oncology 45th Annual Meeting on Women’s Cancer in Tampa, Florida, treating cervical cancer cells with AHCC resulted in the elimination of HPV, human papillomavirus, as well as a decrease in the rate of tumor development in-vitro and in-vivo. Dr. Judith A. Smith, Pharm.D., of the University of Texas Health Science Center (UTHealth) Medical School in Houston conducted the research.

Cervical cancer cells were treated with AHCC and cultured for 72 hours, with samples taken every 24 hours, in the study. The experiment was then replicated in two orthotopic mouse models, one with HPV and one without.

HPV expression was abolished following 90 days of once-daily AHCC dose, with a sustained response after 30 days off therapy. Dr. Smith then repeated the trial to validate the findings and added sampling for correlative testing of immunological markers to investigate how AHCC eradicates the HPV infection.

These findings indicate that AHCC can eradicate HPV infections and may have a role in the prevention of HPV-related malignancies. The UTHealth Women’s Center is conducting a confirmatory pilot research in HPV+ women.

“The results of this study were very encouraging,” stated Dr. Smith, Associate Professor of Medicine at UTHealth. “This study, which began in 2008, shows that AHCC has the potential to treat HPV infection on its own,” she stated. Smith’s prior work looked into AHCC integration with standard chemotherapeutic medicines used to treat ovarian cancer to look for possible medication interactions and activity improvements.

AHCC is an immunotherapy treatment that leverages the body’s own immune system to combat illness. AHCC has been proven in human and in-vivo studies to enhance the number and/or activity of Natural Killer (NK) cells, dendritic cells, and cytokines, allowing the body to effectively respond to infections and inhibit tumor progression.

The most prevalent sexually transmitted virus in the United States is HPV (human papillomavirus). HPV infection affects up to 70% of sexually active individuals at some time in their life. Human papillomavirus DNA was found in 99.7% of cervical cancer samples, indicating the most extensive causal link of any malignancy. According to the CDC, HPV is also linked to 95% of anal cancer, 60% of oropharyngeal cancer, 65% of vaginal cancer, 50% of vulvar cancer, and 35% of penile cancer.

“I was intrigued by research presented at the annual AHCC symposium in Sapporo showing the immune modulating effect of AHCC on other rare infections, and I was eager to study the possibilities in treating the HPV infection associated with cervical cancer,” Dr. Smith explained.

“AHCC is a common, well-tolerated nutritional supplement that has been used for decades in Japan; I am very excited to be pursuing a nutritional approach to trying to find a treatment for HPV infections,” said Dr. Smith, whose research focuses on drug development for gynecologic cancers and conditions, with a particular emphasis on drug interactions/drug resistance and the integration of herbal and nutritional supplements for cancer treatment.

“We had previously demonstrated an antiretroviral regimen that successfully eradicated the HPV infection,” Dr. Smith added, “but we wanted to develop a more benign protocol because these medications have a number of side effects.”

Based on the article of By Emily MullinMar 24, 2014

Leave a Reply

Your email address will not be published. Required fields are marked *